ʻO NovoMix® 30 FlexPen® Insulin e mālama i ʻelua mau manawa

ʻO kēia mea hana: 1 ml o ka pakanika no ka maʻi pūpū he 100 IU / ml o ka insulin aspart (rDNA) (30% soluble insulin aspart a me 70% insulin aspart i ulala ʻia me ka protamine)

1 ka syringe peni he 3 ml, kahi e like ai me nā ʻāpana 300

1 papa (OD) he 6 nmol a 0,035 mg o ka desalted anhydrous insulin aspart,

Nā mea kūʻokoʻa: glycerin, fenol, metacresol, zinc chloride, sodium chloride, sodium phosphate, dihydrate, protamine sulfate, sodium hydroxide, diluted hydrochloric acid, wai no ka injection.

ʻO nā waiwai Pharmacological

ʻO NovoMix ® 30 FlexPen ® kahi hana hoʻokaʻawale lua i ka aspart o ka soluble insulin (short-acting insulin analog) a me aspart crystallized insulin me ka protamine (medium-acting insulin analog). Hoʻopaʻa ka kaʻaila i ka aspart o ka hana hema a me ka lōʻihi o ka lōʻihi o ka hana i ka pae o 30/70. Me ka hoʻopuka ʻana o nā likeʻe molar like ʻole, ka like o ka insulin aspart e like me ka insulin o ke kanaka.

ʻO ka hopena o ke kōne hoʻohaʻahaʻaina o ka insulin e hoʻoikaika i ka kaila o ka glucose e nā kopa ma hope o ka hoʻopaʻa ʻana i ka insulin i ka poʻe ʻono o nā pūpū a me nā momona, a me ka nalo ʻana o ka hoʻokuʻu o ka glucose mai ka ate.

Hoʻomaka ka NovoMix ® 30 FlexPen ® i ka hana 10-20 mau minuke ma hope o ka hoʻokele ʻana o ka lāʻau. Hoʻohālikelike ka hopena kiʻekiʻe loa i nā hola 1-4 ma hope o ka hoʻokele ʻana. ʻO ka lōʻihi o ka hana a hiki i ka 24 hola.

Ma kahi noiʻi haumania i mau mau 3 mau mahina a hoʻohālikelike i ka hoʻokele ʻana o NovoMix ®30 FlexPen ® a me ka bypasic insulin kanaka kanaka 30 ma mua o ka ʻaina kakahiaka a me ka ʻaina i nā mea maʻi me ka maʻi type II a me ka ʻano II, hōʻikeʻike ʻia me ka hoʻomaka ʻana o NovoMix ® 30 FlexPen ® glucose koko. ma hope o ka ʻai ʻelua (ka ʻaina a me ka pāʻina), ʻoi loa ka haʻahaʻa i hoʻohālikelike ʻia i ka mālama ʻia o ka insulin biphasic kanaka 30.

Ke hoʻokō nei i kahi anal-meta, i loaʻa iā 9 mau loiloi lāʻau lapaʻau i nā mea maʻi me ka maʻi type II a me ka type II, ua hoʻomaopopo ʻia, i hoʻohālikelike ʻia i ka insulin kanaka biphasic 30, ka hoʻohana ʻana o NovoMix ®30 ma mua o ka ʻaina kakahiaka a me ka pāʻina e alakaʻi i kahi kahe koko postprandial maikaʻi loa. ka piʻi awelika o ka glucose o ko koko ma hope o ka ʻaina kakahiaka, ka ʻaina a me ka pāʻina).

ʻOiai ke kiʻekiʻe o ka glucose kaʻai ʻana i ka poʻe maʻi e loaʻa ana ka hoʻomaʻemaʻe NovoMix ®30, ka pae o ka hemoglobin glycosylated, he hōʻailona ia o ka hopena o ka glycemic control.

Ma kahi noiʻi haumania, nā maʻi me ka maʻi type II (341 poʻe), i hoʻokaʻawale ʻia i nā pūʻulu e like me ke kumu hina, loaʻa wale nō NovoMix ® 30 a me NovoMix ® 30 i hui pū me metformin a metformin me sulfonylureas. Ma hope o 16 mau pule o ka hoʻōla, ua like ka ʻike o ka neʻe ʻana o HbA 1c i nā mea maʻi e loaʻa ana iā NovoMix ® 30 a me ka metformin a me metformin a me sulfonylurea like ʻole. Ma kēia noiʻi ʻana, ma 57% o nā mea maʻi, ʻoi aku ka kiʻekiʻe o ka HbA 1c ma mua o 9%. I kēia mau maʻi āpau, i ka wā e mālama ai i ka NovoMix ® 30 a me ka metformin, ʻoi aku ka nui o ka pae o ka HbA 1c i ʻoi aku ka nui ma mua o ka hui pū ʻana o ka metformin me sulfonylurea.

Ma kahi noiʻi o nā maʻi maʻi maʻi II, i ka hoʻomohala ʻana i ka glycemic hoʻohana wale ʻana i nā lāʻau hypoglycemic oral wale nō i kūpono ʻole, ua mālama ʻia me ka hoʻomanawanui ʻelua o kēlā me kēia lā ʻo NovoMix 30 (117 nā mea maʻi) a i ʻole ka lawelawe hoʻokahi o kēlā me kēia lā o ka insulin glargine (116 nā mea maʻi). Ma hope o ka 28 mau lapaʻau o ka mālama ʻana, ʻo NovoMix â 30 i ukali ʻia e ka wae koho, ua hoʻemi ʻia ka nui o ka HbA 1C ma ka 2.8% (ʻokoʻa kumu o HbA 1C i ka wā i hoʻokomo ʻia i ka noiʻi = 9.7%). I ka wā o ka mālama ʻana me NovoMix â 30, 66% o nā mea maʻi i hōʻea i nā pae ma ka HbA 1C ma lalo o 7%, a ua hōʻea ka 42% i nā mea maʻi ma lalo o 6.5%, ʻoiai ka wikiwiki o ka wikiwiki o ka glucose glucose i emi e ka 7 mmol / L (mai 14.0 mmol / l ma mua o ka mālama ʻana a hiki i ka 7.1 mmol / l).

Ke hana nei i kahi anal-analahi i nā maʻi me ka maʻi type II, ua ʻike ʻia me ka NovoMix® 30 ka pilikia o ka hoʻomohala ʻana i ka hypoglycemia i ka pō a ua hōʻemi ʻia ka hypoglycemia hoʻohālikelike ʻia i ka insulin kanaka biphasic 30. I ka manawa like, ʻo ka nui o ke ala o nā episode hypoglycemia i ke ao kiʻekiʻe i nā maʻi e loaʻa ana i ka NovoMix ® 30.

Na keiki a ʻōpio. Ua hōʻike ʻia kahi hōʻike 16-wiki ma nā maʻi 167 mau makahiki he 10-18 mau makahiki i hoʻohālikelike ai i ka mālama ʻana i ka mana glycemic postprandial ma o ka lawelawe ʻana iā NovoMix 30 me nā meaʻai e hoʻohana ana i ka insulin kanaka / biphasic kanaka 30 me kaʻai me ka insulin NPH ma mua o ka hiamoe. I ka manawa o ke aʻo ʻana i nā pūʻulu ʻelua, ua hoʻomau ka neʻe o ka HbA 1C ma ka pae i komo i loko o ka hoʻopaʻa ʻana, me ka ʻole o nā ʻokoʻa a ka hanana o ka hypoglycemia ma waena o NovoMix 30 a me ka biphasic i loko o ke kanaka 30.

Ma kahi noi ʻelua-makapō ʻole ʻelua (12 mau pule no kēlā me kēia papa) i hana ʻia ma kahi pūʻulu liʻiliʻi o nā keiki (54 mau kānaka). I ka makahiki 6-12, ua hoʻonui ʻia ka nui o nā episodole o ka hypoglycemia a me ka hoʻoliʻi kūlohelohe i ka helu ma mua o ka mālama ʻia me NovoMix â 30 ua hoʻohālikelike ʻia me ka inika olakino biphasic 30. ʻO ka pae o HbA 1C i ka hopena o ka papa o ka mālama ʻana i ka hoʻokaʻawale ʻana i ka hui e loaʻa ana i ka insulin o ka biphasic kanaka 30 ma mua o ka hui e loaʻa nei iā NovoMix â 30.

ʻO nā elemakule. ʻAʻole i aʻo ʻia nā pharmacodynamics o NovoMix â 30 i nā maʻi maʻi. Eia nō naʻe, ua hana ʻia kahi noi pālolo manuahi ʻelua ma kahi e hoʻohālikelike ai i ka pharmacokinetics a me nā pharmacodynamics o ka aspart insulin a e hoʻoponopono i ka insulin kanaka ma 19 mau maʻi me ka maʻi II type mellitus ʻone he 65-83 mau makahiki (ʻo ia hoʻi ka makahiki 70 mau makahiki). ʻO nā kūlike pili i ka lāʻau lapaʻau (GIR max, AUC GIR, 0-120 min) ma hope o ka hoʻokele ʻana o ka insulin aspart a i ʻole he kanaka a i kēia mau maʻi ua like like me nā poʻe olakino a maʻi paha me ka maʻi ʻōpio.

I loko o ka aspart insulin, e hoʻomoʻa ka hinu waikela amino ma kahi o ka 28 o ka mākela o B o kahi molololi i ka lula e ka aspartic acid, e hoʻoneʻeneʻe ana i ka hana hexamers, e like me ka mea i ʻike ʻia i ka hoʻomākaukau ʻana o ka hoʻomākaukau ʻana i ka insulin kanaka. Ma ka hopena o ka mahina o ka NovoMix 30, ʻo ka hapa o ka aspart o ka insulin he 30% o ka insulin a pau, ua hoʻokomo ʻia i loko o ke koko mai ka subcutaneous tissue wikiwiki aʻe ma mua o ka soluble insuline o ka biphasic insulin. ʻO 70% ka waiho ʻana ma ke ʻano he crystalline o ka protart-insulin aspart, ʻo kahi mea hou aku ka lōʻihi o ka like me ka NPH insulin like kanaka. ʻO ka nui loa o ka insulin i ka serum o ke koko ma hope o ka hoʻomaka ʻana o NovoMix 30 he 50% ʻoi aku ke kiʻekiʻe, a ʻo ka manawa e hōʻea ai, ʻo ia ka hapalua o ia ke kanaka o ka bifasic insulin i loko o nā limahana olakino. loaa ka serum insulin aspart ma hope o 60 mau minuke, ʻo iaʻo 140 ± 32 pmol / L. ʻO ka hapalua o ka ola o NovoMix ® 30 (t½), e hōʻike ana i ka helu o ka loaʻa ʻana o ka hapa protamine, ma kahi o 8-9 mau hola. Hoʻi hou nā pae insulin Serum i ka baseline 15-18 mau hola ma hope o ka hoʻokele subutanutan. I ka poʻe maʻi me ka maʻi type 2, ua hōʻea ka nui o ka piʻi ʻana i nā minuke 95 ma hope o ka hoʻokele ʻana a noho i luna o ke kahua no ka liʻiliʻi he 14 mau hola.

ʻO nā elemakule. ʻAʻole i aʻo ʻia ka pharmacokinetics o NovoMix â 30 i nā maʻi maʻi maʻi. Eia naʻe, nā hopena pili i ka waiwai o ka pharmacokinetics ma hope o ka hoʻomalu ʻana o ka insulin aspart a i ʻole insulin manu kanaka i nā mea maʻi me ka type II diabetes mellitus (65-83 mau makahiki heʻelemakule, ʻo 70 mau makahiki he mau makahiki like ia me nā mea olakino a maʻi paha me ka maʻi maʻi ʻōpio. I ka poʻe maʻi a me nā poʻe senile, e emi ana ka nui o ka lilo ʻana, e like me ka mea i hōʻike ʻia e ka manawa lōʻihi aku i ka lōʻihi o ka pae ʻana o ka insulin i ke koko t max (82 min me kahi ākea interquartile o 60-120 min). ʻO ka waiwai o C max he like like me nā mea maʻi me ka diabetes type type 2 o kahi ʻōpio a ʻōpio a i lalo iki iho i nā mea maʻi me ka maʻi maʻi type 1.

Hoʻopiʻi maikaʻi ʻole a me ka hana hepatic.

ʻAʻole i aʻo ʻia nā pharmacokinetics o NovoMix ® 30 i nā mea maʻi i nā renal impaired a i ʻole hepatic function.

Na keiki a ʻōpio. ʻAʻole i aʻo ʻia nā pharmacokinetics o NovoMix â 30 i nā keiki a me nā ʻōpio. Eia nō naʻe, i nā keiki (6-12 mau makahiki) a me nā ʻōpio (13-17 mau makahiki) me ka ʻano type type 1, ua noiʻi ʻia nā pharmacokinetics a me pharmacodynamics o ka insulin aspart soluble. Ua wikiwiki koke ia i loko o nā mea maʻi o nā hui ʻelua, ʻoiai hoʻi ka helu o ka max he mea like ʻole i ka pākeke. I ka manawa, ua nui ka nui o ka C C i nā pūʻulu o nā makahiki like ʻole, e hōʻike ana i ke koʻikoʻi o nā koho kanaka ʻokoʻa i ka pānīnē o ka insulin aspart.

ʻO ka ʻikepili palekana preclinical.

ʻO ka ʻimi preclinical i loaʻa ma ke kumu o nā noi maʻamau e pili ana i ka palekana pharmacology, ka maʻi o ka hopohopo pinepine o ka lāʻau lapaʻau, ka genotoxicity a me ka huikala o ka reproduction, ʻaʻole i hōʻike i kahi ka hopena o ke kanaka.

I loko o nā hōʻike vitro, me ka pili ʻana i ka insulin a me ka IGF-1 ʻokoʻa a me nā hopena e pili ana i ka ulu ʻana i nā cell, ua hana ʻia ka like me ka insulin. Ua hōʻike ʻia nā noiʻi ʻo ka wehe ʻana o ka hoʻopaʻa ʻana i nā mea i hoʻopaʻa ʻia i ka insulin no ka aspart insulin e like me ka insulin kanaka.

Pākuʻi helu

Hoʻopaʻa no ka hoʻokele subcutaneous, 100 PIECES / ml

1 ml o ke kaawale ʻaole

mea waiwai - insulin aspart 100 U (3.5 mg) (30% kūmole i ka aspart insulin a me 70% insulin aspart e hoʻohana ʻia me ka protamine),

nā mea hoʻohālikelike: zinc, glycerol, fenol, metacresol, sodium hydrogen phosphate dihydrate, sodium chloride, protamine sulfate, hydrochloric acid, sodium hydroxide, wai no ka hōʻemi.

ʻO kahi pīhoihoi ka homogeneous keʻokeʻo, i ka wā e waiho ai, e hoʻopili ʻia i loko o kahi aniani, i ʻole ʻulaʻula a i ʻole nā ​​waihoʻoluʻu ʻulaʻula a me kahi kahi keʻokeʻo keʻokeʻo. Ke kāwili ʻana i nā ʻike o ka peni, pono kahi ʻōmaʻomaʻa homogeneous.

ʻLoe a me ke kākele

Hoʻonohonoho ʻia ka NovoMix® 30 FlexPen® wale no no ka hoʻokele subcutaneous. ʻAʻole pono e hoʻokele pono ʻia ʻo NovoMix® 30 FlexPen® ma muli, no ka mea hiki i kēia ke alakaʻi i ka hypoglycemia koʻikoʻi. Pono e hoʻokaʻawale nā ​​keʻena Intramuscular o NovoMix® 30 FlexPen®. Mai hoʻohana i ka NovoMix® 30 FlexPen® no ka infusion insulin infusion (PPII) i loko o nā poma.

Kuhi ʻia ka hopena o ka lāʻau e ka kauka ponoʻī i kēlā me kēia hihia, e pili ana i ka pae o ka glucose i ke koko.

ʻO ka poʻe maʻi e loaʻa ana i ka maʻi type 2, ʻo NovoMix® 30 FlexPen® hiki ke kuhikuhi iā ia e like me ka monotherapy a me ka hui pū ʻana me nā lāʻau hypoglycemic waha i nā hihia i ka hopena o ka glucose o ke koko ʻaʻole i hoʻoponopono pono ʻia e nā lāʻau hypoglycemic waha wale nō.

No nā poʻe maʻi me ka maʻi diabetes type 2, ʻo ka lāʻau i hoʻomaka ʻia e NovoMix® 30 FlexPen® he 6 mau kakahiaka i ke kakahiaka a he 6 mau pūʻulu i ke ahiahi (me ka ʻaina kakahiaka a me ka pāʻina, me kēlā). Hoʻouna ʻia ia e lawe i mau ʻāpana he 12 o ka NovoMix® 30 FlexPen® i hoʻokahi lā i ke ahiahi. Ma kēia hope aku, akā naʻe, ma hope o ka lawe ʻana i 30 mau lāʻau o ka lāʻau lapaʻau, pono ʻia e hoʻololi i ka lawe ʻana i ka NovoMix® 30 FlexPen® ʻelua manawa i ka lā, e hoʻokaʻawale i ka maʻi ma nā wahi like (me ka ʻaina kakahiaka a me ka ʻaina, kēlā me kēia). Ke hele maluhia nei e lawe i ka NovoMix® 30 FlexPen® ʻekolu mau manawa i ka lā e hiki ke hoʻokaʻawale ma ke ʻano o ka wana i kakahiaka i ʻelua mau wahi like ʻole a lawe i kēia mau ʻāpana ʻelua i ke kakahiaka a me ke ahiahi.

I nā maʻi me ka kūʻē o ka insulin (no ka laʻana, ma muli o ka momona), e hoʻonui ʻia ka pono o kēlā me kēia lā no ka insulin, a i loko o nā mea maʻi me ka hoʻoneʻe endogenous huna ʻana o ka insulin, e hoʻemi ʻia.

Hoʻomaopopo ʻia ka papa ʻao e pili ana i ka hoʻoponopono ʻana o ka maʻa:

Kaʻai koko ma mua o ka papaʻaina

Hoʻoponoponodosis NovoMix® 30

E lawelawe koke ʻia ʻo NovoMix® 30 FlexPen® ma mua o ka papaʻaina. Inā pono, hiki ke lawelawe ʻia ʻo NovoMix® 30 FlexPen® ma hope o ka hoʻomaka ʻana o ka ʻai.

Pono ka wela o ka insulin i ka mahana ma waena o ka lumi.

ʻO NovoMix® 30 FlexPen® e hoʻokele e lawelawe me ka ʻōpala o ka ʻūhā a i ʻole ka paia ʻōpū. Inā makemake, hiki ke lawelawe ʻia ka lāʻau lapaʻau i nā poʻohiwi a i ʻole nā ​​kuaʻi.

Pono e hoʻololi i ka pae injection i loko o ka wahi o anatomical i mea e pale ai i ka hoʻomohala ʻana o ka lipodystrophy.

E like me kekahi hoʻomākaukau ʻē aʻe o ka insulin, ka lōʻihi o ka hana a NovoMix® 30 FlexPen® ma muli o ka maʻa, kahi o ke keʻena ʻana, ka ikaika o ke kahe, ke ʻano a me ka pae o ka hana kino. ʻO ke hilinaʻi o ka hoʻopili ʻana o NovoMix® 30 FlexPen® ma ka wahi i hoʻopaʻa ʻia ʻaʻole i aʻo ʻia nā ʻike.

Hiki ke koi ʻia ka hoʻoponopono ʻana inā he maʻi nā mea maʻi i nā maʻi, nā ate, ka hana adrenal functioning, ka pituitary gland a i ʻole thyroid gland.

Hiki pū paha ke pono no ka hoʻoponopono hoʻoponopono ʻana i ka wā e hoʻololi ai i ka hana kino a i ka ʻai maʻamau o ka mea maʻi. Hiki ke koi ʻia ka hoʻoponopono ʻana i ka neʻe ʻana i ka mea maʻi mai kahi ʻano like ʻole o ka insulin i kekahi.

Nā mea maʻi a me nā senile

Hiki i ka NovoMix® 30 FlexPen® ke hoʻohana i nā maʻi maʻi makua, akā naʻe, ʻike me kona hoʻohana ʻana i ka hui pū ʻana me nā lāʻau hypoglycemic waha i nā mea maʻi ma mua o 75 mau makahiki ua palena ʻia.

I nā maʻi me ka maʻi ʻole o ka maʻi hepatic, hiki ke hoʻopau ʻia ka manaʻo no ka insulin.

I nā poʻe maʻi āpau, pono ia e nānā i nā pae o ka glucose koko a hoʻoponopono i ke ʻano o ka insulinart aspart e pili ana i ka ʻikepili pilikino.

Na keiki a ʻōpio

Hiki i nā NovoMix® 30 FlexPen® ke mālama i nā keiki a me nā ʻōpio i nā makahiki he 10 i nā makahiki i kahi e makemake ʻia ai ka hoʻohana ʻana o ka insulin mua. Loaʻa nā ʻikepili lāʻau koʻikoʻi no nā keiki he 6 a 9 mau makahiki paha.

Nā akahele no ka hoʻohana ʻana:

ʻO NovoMix® 30 FlexPen® a me nā pono he pono no ka hana pilikino wale nō. Mai hoʻihoʻi i ka pahu penika ʻo nā syringe.

ʻAʻole hiki ke hoʻohana ʻia ʻo NovoMix® 30 FlexPen® inā ma hope o ke kāwili ʻana ʻaʻole ia i keokeo a keokeo a me ke ao.

Pono pono e hoʻokaʻawale i ka NovoMix® 30 FlexPen® pani ma mua o ka hoʻohana. Mai hoʻohana i ka NovoMix® 30 FlexPen® inā ua maloʻo ia. E kiola aku i ka pono ma hope o kēlā me kēia inake.

Nā hopena hopena

ʻO nā hopena ʻino e nānā ʻia ana i nā maʻi me ka hoʻohana ʻana iā NovoMix® 30 FlexPen® i ka nui o ka hilinaʻi nui a ma muli o ka hopena pharmacological o ka insulin.

ʻO nā huaʻehā ka hopena o ka pinepine o ka hopena ʻino i hōʻike ʻia i ka wā o nā hoʻokolohua lapaʻau, i ʻike ʻia me ka hoʻohana ʻana o NovoMix® 30 FlexPen®. ʻO ka neʻe o ka neʻe i koho ʻia penei: pinepine pinepine (≥ 1/10), pinepine pinepine (≥ 1/100 a

E hoʻokuʻu i ke ʻano, ka pale a me ka hoʻonohonoho

ʻO ka hoʻokuʻuʻana i ka s / c kaila keʻokeʻo, ʻokoʻa homolo (ʻaʻohe kīpili, ʻike ʻia ka palaki ʻia i loko o ke ʻano hoʻohālike), i ka wā i hoʻokaʻawale ʻia, hoʻokaʻawale, hana i kahi kūmole keʻokeʻo a i ʻole ka lau i ʻole ka ʻulaʻoniʻoni ʻole, me kahi kāwili mālie e hoʻokūkū, e hana i kahi hoʻopiʻi kūʻokoʻa.

Nā mea kūʻai: ka glycerol - 16 mg, fenol - 1.5 mg, metacresol - 1,72 mg, zinc klorida - 19.6 μg, sodium chloride - 0.877 mg, sodium hydrogen phosphate dihydrate - 1.25 mg, protamine sulfate

0.33 mg sodium hydroxide

2.2 mg, ka pākuʻi hydrochloric

1,7 mg, ka wai d / i - hiki i ka 1 ml.

3 ml (300 PIECES) - nā pahu uila (5) - blisters (1) - nā pākeke o ka pāpale.

Ka hana lāʻau lapaʻau

ʻO ia ka lua o ka hoʻokuʻuʻana i ke anuanu o ka hoʻohui i nā analogue: soluble insulin aspart (30% pōkole ka hana pono insulin) a me nā crystals insulin o ka aspart protamine (70% medium-acting insulin analog).

Hōʻike ka emi ʻana o ke kaʻe o ke koko ma muli o ka hoʻonui ʻana o kāna kaomi intracellular ma hope o ka paa ʻana o ka insulin aspart biphasic me nā ʻĀina e hoʻoneʻe ana i ka uaua o ka naʻau a me ka pā adipose a me ka like o ka hoʻokaʻawale ʻana o ka hana glucose ma ka ʻāʻī.

Loaʻa ka hopena

Ma ka ʻāpana o ka ʻōnaehana: maʻamau - pinepine - urticaria, ʻāhaʻi kino, ʻūhā ma luna o ka ʻili, ʻike liʻiliʻi loa - nā hopena anaphylactic.

Mai ka ʻaoʻao o ka metabolism a me kaʻaiʻai: pinepine pinepine - hypoglycemia.

Mai ka ʻaoʻao o ka wahī nīnaena: paʻakikī - peripheral neuropathy (neuropathy hōʻeha ulu).

Mai ka ʻaoʻao o ka io o ka hihiʻo: pinepine - paʻakikī refractive, diabetic retinopathy.

Mai ka ʻili a me nā ʻili subcutaneous: pinepine - lipodystrophy.

ʻO nā hopena maʻamau: pinepine - edema.

ʻŌpū a me ka lactation

Hoʻohui wale ka ʻike maʻi maʻi me ka hāpai ʻana.

I ka wā o ka hoʻomaka ʻana o ka hāpai ʻana a i kēlā wā holoʻokoʻa, pono ia e nānā pono i ke ʻano o nā mea maʻi me ka maʻi mellitus a nānā aku i ka kaʻe o ka glucose i loko o ke koko. Ka pono o ka insulin, ma ke ʻano he kānāwai, e ho'ēmi i ka trimester mua a hoʻonui pinepine i ka trimesters lua a me ke kolamu o ka hapai. Ma hope iho o ka hānau ʻana, hoʻi hou ka pono no ka insulin i ka pae ma mua o ka wā hāpai.

I ka wā mālama aʻai, hiki ke hoʻohana ʻia me ka ʻole o ka palena. ʻAʻole ka hoʻoweliweli i ka insulin i ka makuahine hānai i ka pēpē. Eia naʻe, pono paha kahi hoʻoponopono hoʻoponopono.

Hoʻohana i nā keiki

ʻAʻole ia e hāʻawi ʻia i nā keiki i lalo o ka 6 mau makahiki o ka ʻaʻole i lawe ʻia nā hoʻokolohua maʻi.

Hiki ke hoʻohanaʻia e mālama i nā keiki a me nā ʻōpio i nā makahiki he 10 i nā makahiki i mea e makemake ʻia ai ka hoʻohana ʻana o ka insulin mua. Loaʻa nā ʻikepili lāʻau koʻikoʻi no nā keiki he 69 mau makahiki.

Nā ʻōlelo kikoʻī

Ma mua o kahi huakaʻi lōʻihi e pili ana i ka loli ʻana o nā manawa maʻamau, pono ke kamaʻilio e kamaʻilio me ko lākou kauka, ʻo ke hoʻololi ʻana i ka palena o ka manawa e pono ai e ʻai ka mea maʻi a lawelawe hoʻi i ka insulin i kahi manawa ʻē aʻe.

ʻAʻole lawa ka wai o ka lāʻau a i ʻole ka lohi ʻana o ka mālama ʻana, ʻoiai me ka type 1 diabetes mellitus, hiki ke alakaʻi i ka hoʻomohala ʻana i ka hyperglycemia a i ʻole ketoacidosis maʻi maʻi. Ma ke kānāwai, ʻike pinepine ʻia nā hōʻailona mua o ka hyperglycemia, ma luna o nā hola a i ʻole mau lā. ʻO nā hōʻailona o ka hyperglycemia ke ʻano o ka makewai, ka nui o ka nui o ka urine i hoʻokuʻu ʻia, ka nausea, ka luaʻi, ka hiamoe, ʻulaʻula a me ka maloʻo o ka ʻili, ka puʻu maloʻo, ka nalowale o ka makemake, a me ke ʻano o kahi ʻāpana o ka acetone i ka ea hanu. Ma ke ʻano o ka mālama kūpono, ʻo ka hyperglycemia i nā maʻi me ka maʻi diabetes type 1 hiki ke alakaʻi i ka ketoacidosis maʻi, kahi kūlana e make ai.

Hōʻalo i ka meaʻai a i ʻole ka hoʻolālā ʻana i ke ʻano ikaika loa hiki ke alakaʻi i ka hypoglycemia. Hiki i ka hypoglycemia ke kūkulu hou inā he kiʻekiʻe loa ka nui o ka inika e pili ana i nā pono o ka mea maʻi.

Ma hope o ka hoʻopiʻi ʻana i ka ʻai o ka lolo, no ka laʻana, me ka hoʻomehana ʻana o ka insulin, hiki i nā maʻi ke maʻi
nā hōʻailona maʻamau o ka mea mua o ka hypoglycemia hoʻololi, kahi e ʻike ʻia ai e nā mea maʻi. E nalo paha nā hōʻailona luhi maʻamau me ka lōʻihi o ka maʻi maʻi.

ʻO nā maʻi e like me ka maʻi hopohopo a hele pū ʻia me ke kuni, e hoʻonui pinepine i ke kino o ka maʻi o ka insulin. Hiki ke koi ʻia i ka hoʻoponopono ʻana inā he maʻi nā mea maʻi i nā maʻi, nā ate, ka hana adrenal functioning, ka pituitary gland a i ʻole thyroid gland.

Ke hoʻoneʻe nei i ka mea maʻi i nā ʻano like ʻole o ka insulin, e loli a hōʻailona paha ka hoʻomaka ʻana o ka maʻi o ka poʻe precogors no ka hypoglycemia a i ʻole ka liʻiliʻi ʻia i hoʻohālikelike ʻia i ka poʻe e hoʻohana ana i ka ʻano o ka insulin mua.

ʻO ka hoʻoneʻe ʻana o ka mea maʻi i kahi ʻōiwi hou a i ʻole ka hoʻomākaukau ʻana i ka insulin o kekahi mea hana hou e hana ʻia ma lalo o ka mākaʻi loea paʻa. Inā ʻoe e hoʻololi i ka nānā, ʻano, hana a me nā ʻano (insulin a kanaka, kahi mea hoʻohui o ke ahina o ke kanaka) no ka hoʻomākaukau ʻana o ka insulin a me / a i ʻole ke ʻano o ka hana ʻana, pono paha i kahi loli ka palena.

Ua hōʻike ʻia nā pilikia o ka hoʻomohala ʻana i ka puʻuwai naʻau i ka mālama ʻana i nā mea maʻi me ka thiazolidinediones i hui pū me ka hoʻomākaukau ʻana i ka insulin, ʻoiai inā he mau pilikia ko ia mau maʻi no ka hoʻomohala ʻana o ka naʻau puʻuwai. Pono kēia ʻoiaʻiʻo e noʻonoʻo i ka wā e koho ana i ka hui hoʻohui me thiazolidinediones a me ka hoʻomākaukau ʻana o ka insulin i nā mea maʻi. Ke koho ʻana i ia mea hui, pono e hana i nā hoʻokolohua olakino e pili ana i nā maʻi e hoʻomaopopo i nā hōʻailona a me nā hōʻailona o ka puʻuwai puʻuwai kino, loaʻa ke kaumaha a me ka noho ʻana o ka edema. Inā hele i nā hopena o ka puʻuwai naʻau i loko o nā mea maʻi, pono e hoʻokaʻawale ke ʻano me ka thiazolidinediones.

Hoʻopilikia i ka hiki ke hoʻokau i nā kaʻa a me nā māka

Hiki i ka poʻe maʻi ke nānā i ka helu a me ka hopena i ka wā o ka hypoglycemia, he hiki ke kūleʻa i nā kūlana i nā mea e pono ai kēia mau mana (no ka laʻana ke kime ʻana i nā kaʻa a i ʻole ka hana me nā mīkini a me nā mīkini.

Pono e ʻōlelo ʻia nā mea maʻi e hana i nā hana e pale ai i ka hoʻomohala ʻana o ka hypoglycemia i ka wā e holo ana. He mea koʻikoʻi loa kēia no nā mea maʻi me ka ʻole a hōʻemi iki paha i nā hōʻailona mua e kūkulu ai i ka hypoglycemia a i ʻole ka hōʻeha ʻana i nā manawa pinepine o ka hypoglycemia. I kēia mau hihia, pono ke noʻonoʻo ʻia ka kūpono o ka hoʻokele a hana i kēlā hana.

Hoʻohui nūhou

Nui kekahi mau lāʻau lapaʻau e pili pono ana i ka pono o ka insulin. Hypoglycemic hopena o ka insulina ka hōʻoi 'ku una ha hypoglycemic ai', Mao nā mea kūpale, ACE nā mea kūpale, carbonic anhydrase nā mea kūpale i ole e wae Hoʻokolohua-blockers, bromocriptine, sulfonamides, anabolic steroid, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, ai 'likiuma salicylates . ^ E Ha yM.

Ua palupalu ʻia ka hopena hypoglycemic waha e ka contraceptives waha, glucocorticosteroids, he thyroid hormones, thiazide diuretics, heparin, tricyclic antidepressants, sympathomimetics, somatropin, danazole, clonidine, slow calcium channel blockers, diazoxide, morphine.

Hiki i nā beta-blockers ke uhi i nā hōʻailona o ka hypoglycemia.

Hiki i ka Octreotide / lanreotide ke hoʻonui a hoʻopau i ka pono o ke kino no ka insulin.

Hiki i ke alakika ke hoʻonui a hōʻemi paha i ka hopena hypoglycemic o ka insulin.